MARKET

LEGN

LEGN

Legend Biotech Corp
NASDAQ
21.42
-0.23
-1.06%
Pre Market: 21.50 +0.08 +0.37% 08:49 12/18 EST
OPEN
21.67
PREV CLOSE
21.65
HIGH
22.02
LOW
21.39
VOLUME
1.62K
TURNOVER
0
52 WEEK HIGH
45.30
52 WEEK LOW
21.39
MARKET CAP
3.96B
P/E (TTM)
-16.4529
1D
5D
1M
3M
1Y
5Y
1D
Top 3 Health Care Stocks You'll Regret Missing This Quarter
Benzinga · 3h ago
Legend Biotech Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones · 1d ago
Legend Biotech Price Target Cut to $74.00/Share From $75.00 by Cantor Fitzgerald
Dow Jones · 1d ago
Cantor Fitzgerald Maintains Overweight on Legend Biotech, Lowers Price Target to $74
Benzinga · 1d ago
Legend Biotech CEO to Present Company Updates at J.P. Morgan Healthcare Conference
Reuters · 1d ago
Legend Biotech price target lowered to $74 from $75 at Cantor Fitzgerald
TipRanks · 1d ago
Piper Sandler Reaffirms Their Buy Rating on Legend Biotech (LEGN)
TipRanks · 1d ago
Legend Biotech management to meet with Cantor Fitzgerald
TipRanks · 2d ago
More
About LEGN
Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

Webull offers Legend Biotech Corp (ADR) stock information, including NASDAQ: LEGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LEGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LEGN stock methods without spending real money on the virtual paper trading platform.